ARTICLE | Clinical News

Subcutaneous elamipretide: Ph I started

November 15, 2016 9:24 PM UTC

Stealth began the open-label, U.S. Phase I ReCLAIM trial to evaluate 40 mg subcutaneous elamipretide once daily for 12 weeks in about 40 patients ages ≥55....

BCIQ Company Profiles

Stealth BioTherapeutics Corp.

BCIQ Target Profiles